FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
31/10/2025
Voltar para busca
Dado oficial do USPTO
BDC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
19/12/2023
Data de registro
01/04/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/04/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
ANDREACCHI, SAMANTHA ALEXIS
Unidade examinadora
O30
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Bicycletx Limited
Representantes
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for use in oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the treatment of cancer; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical preparations for use in preventing and treating infections; pharmaceutical products and preparations for the treatment of respiratory disease; pharmaceutical preparations for the treatment and prevention of cardiovascular disease; pharmaceutical preparations for the treatment and prevention of metabolic disease; pharmaceutical products and preparations for the treatment and prevention of viral infections; pharmaceutical preparations for use in medical diagnostics and imaging; pharmaceutical preparations for the treatment and prevention of renal disease; pharmaceutical preparations for the treatment and prevention of gastrointestinal disease; pharmaceutical preparations for the treatment and prevention of muscular skeletal disease
Classe 42
Scientific and technological services and research and design relating theretoscientific research and new product design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; medical research servicesindustrial analysis and research services in the field of medicine; research and development services in the field of pharmaceutical preparations; medical research services; pharmaceutical research servicespharmaceutical testing and clinical trials; scientific research in the nature of conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; scientific research consultingproviding information consultancy and advisory services relating to the aforesaid in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
14/10/2025
FIMP
FINAL DISPOSITION PROCESSED
14/10/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
19/09/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/09/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/09/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/07/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/04/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
01/04/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/03/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
26/03/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/03/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/03/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/03/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/03/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/02/2025
PUBO
PUBLISHED FOR OPPOSITION
11/02/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/02/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/01/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
21/01/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
21/01/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
21/01/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
21/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/12/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/12/2024
RFNT
REFUSAL PROCESSED BY IB
17/08/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
30/07/2024
RFRR
REFUSAL PROCESSED BY MPU
30/07/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/07/2024
CNRT
NON-FINAL ACTION WRITTEN
02/07/2024
DOCK
ASSIGNED TO EXAMINER
01/07/2024
MAFR
APPLICATION FILING RECEIPT MAILED
18/04/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/04/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/04/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BDC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.